Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

This article was originally published in The Pink Sheet Daily

Executive Summary

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Advertisement

Related Content

Chiron’s European Flu Vaccine Dose Expectations Cut By 8 Mil.
Fluvirin FDA Manufacturing Inspections Expected By July
Chiron Begins Fluvirin Manufacturing After U.K. Clears Site
Chiron Optimistic About Re-entering U.S. Flu Vaccine Market In 2005
ID Biomedical Has 1.2 Mil. Extra Doses Of Fluviral For This Season
FDA's Cure For The Flu: Orphan Drug-Like Incentives, Tissue-Based Production
Merck To Triple Pneumococcal Vaccine Supply To 18 Mil. Doses
Roche Could Increase Supply Of Tamiflu To U.S. Market
Flu Vaccine Shortage Shows Hazards Of Market Concentration, Sen. Leahy Says
HHS Seeks Increase In Sanofi-Aventis’ Fluzone Production

Topics

Advertisement
UsernamePublicRestriction

Register

PS061210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel